course

  • HOME
  • course
  • Department of Gastroenterology and Hepatology
CATEGORY

Department of Gastroenterology and Hepatology

Department of Gastroenterology and Hepatology

Staff

The fields of our studies are the gastrointestinal (GI) tract and the hepatobiliary system. Our research themes are as follows.

  1. Study of intestinal flora evaluated by next-generation sequencing using brushing samples taken from patients with inflammatory bowel disease (IBD) during colonoscopy or balloon enteroscopy to clarify the pathology and establish risk markers
  2. Study of functional GI diseases, especially irritable bowel syndrome (IBS) by examining the association with allergic diseases, intestinal flora, inflammatory cytokines, gene expression and polymorphism evaluated by metagenome analysis to elucidate the pathogenesis and to establish novel treatments
  3. Study of colon polyps and cancers examining sarcopenia and visceral obesity in clinical studies to confirm the association with cancer development and examining development of tumors in the mouse with exercise load and fecal microbiota transplantation.
  4. Study of H. pylori related chronic gastritis and gastric cancer examining macroscopic and histological risk markers using image-enhanced endoscopy as well as serum markers including exosomal miRNA to establish cancer prevention and screening, especially after eradication
  5. Study of colon imaging by evaluating the diagnostic ability of capsule endoscope and CT colonography and the accuracy of diagnosis using artificial intelligence (AI) to establish more accurate colon cancer screening
  6. Study of anticancer immunity activation based on the metabolic reprogramming
  7. Preclinical development of an anticancer therapy against existing drug-resistant hepatocellular carcinoma by glycolysis inhibitor (2-deoxy-D-glucose; 2DG)-encapsulated poly(lactic-co-glycolic acid) nanoparticles (2DG-PLGA-NP)
  8. Study of the effect of mitochondrial quality control on the progression of chronic liver disease and hepatocarcinogenesis
  9. Development of an anticancer therapy against existing drug-resistant hepatocellular carcinoma using glycolysis inhibitor (2-deoxy-D-glucose; 2DG)-encapsulated poly(lactic-co-glycolic acid) nanoparticles (2DG-PLGA-NP)
  10. Development of novel early diagnostic markers and therapeutic/diagnostic devices for pancreatobiliary carcinoma
  11. Development of novel screening methods for early-stage pancreatic cancer

The readers are very welcome to collaborate with us if they have interest in our research.